Image

Global Demyelinating Diseases Therapeutics Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Demyelinating Diseases Therapeutics Market, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029

Demyelinating Diseases Therapeutics Market

Demyelinating Diseases Therapeutics Market Analysis and Size

The global demyelinating diseases therapeutics market is expected to witness significant growth during the forecast period. It has been seen that a combination of genetic and environmental factors is responsible for the condition's incidence. The symptoms that are witnessed may differ from patient to patient. Although some of the common symptoms include blurred double vision, ataxia, dysarthria, loss of sensation, hand paralysis, impaired muscle coordination, and speech and hearing disorders. The sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally, causing interruptions in import and export activities of the global demyelinating diseases therapeutics market.

Data Bridge Market Research analyses a growth rate in the global demyelinating diseases therapeutics market in the forecast period 2022-2029. The expected CAGR of the global demyelinating diseases therapeutics market tends to be around 10.50% in the mentioned forecast period. The market was valued at USD 0.71 billion in 2021, and it would grow up to USD 1.58 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Demyelinating diseases are the kind of diseases that affect the nervous system, typically damaging the myelin sheath of neurons. Therefore, causing distortion of signals in the affected nerves further leads to the deficiency in cognition, sensation, and movements or impairing any other physical function carried out by the affected nerve. In addition to this, demyelinating diseases may occur due to genetic irregularities, or infectious agents and many times by autoimmune reactions. There are some cases present wherein the cause may remain unknown. This disease occurrence is rising and important diagnostic procedures and treatments will boost the growth of the market.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Actelion Pharmaceuticals Ltd (Switzerland)

Market Opportunities

  • Increase in Elderly Population
  • Increasing Demand of Corticosteroids

Global Demyelinating Diseases Therapeutics Market Dynamics

Drivers

  • Rising Prevalence for Online Pharmacies

The online pharmacies segment is projected to grow high over the forecast period 2022-2029. This is due to the rapid growth of technology and the availability of drugs in online pharmacies. Such popularisation of online pharmacies and rising demand for various drugs such as glatiramer acetate, immunosuppressants, immunomodulators and other therapeutics from online pharmacies boost the growth of the demyelinating diseases therapeutics market.

  • Increase in the number of research and development activities       

The ongoing research and development programs for improving the current drugs used for the treatment of demyelinating diseases are considered to be boosting the market's growth. In addition to this, novel drugs in R&D pipeline is projected to favour the global demyelinating diseases in the near future. For instance, the latest introduction of monoclonal antibodies (MAbs) is a major factor considered to boost the market growth. These latest drugs are assuring higher efficacy as compared to current therapies.

Opportunities

  • Increasing Demand of Corticosteroids

The corticosteroids segment is considered to be a dominant market share in the year 2021. This is due to the effectiveness of corticosteroids such as prednisone and prednisolone on demyelinating diseases. Several studies were performed, and it was witnessed that the use of corticosteroids leads to improvement in 60% of patients and remission in 61% of treatment participants. The rising effectiveness of corticosteroids increases the growth of the demyelinating disease therapeutics market share. All these factors are also contributing in the growth of the market.  

  • Growing Elderly Population

Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies. Thus, this set of population demands high use of demyelinating disease therapeutics and in return creates more opportunities for market growth.

Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to perform these treatments could curb the growth of the global demyelinating diseases therapeutics market over a forecast period.

  • Limited Options For Treatment

There are limited treatment options available for demyelinating diseases, which remains the major concern for most players in the market. In addition to this, most contemporary demyelinating diseases drugs and therapies available in the market do not assure complete cure of such disorders. Thus, it hampers the market growth.

  • High Cost of Treatments

The cost for diagnosis and treatment of demyelinating disease is very high. According to the Institute for Clinical and Economic Review (ICER) record, in 2019, the average annual cost of a rare disease treatment for each treated patient was $32,000, ranging from $6,000 to $500,000 per year. Such high diagnosis costs and high cost of treatment may restrict the demyelinating diseases therapeutics market growth over the forecast period 2022-2029.

This global demyelinating diseases therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global demyelinating diseases therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Demyelinating Diseases Therapeutics Market

During the pandemic, it has been witnessed that besides the pulmonary, renal, and hematological complications, gastrointestinal, there has been also a record of neurological appearances have also been reported frequently. The patients' most common neurological signs were weakness, sensory deficit, autonomic dysfunction, sphincter dysfunction, and ataxia. Pathogenetic mechanisms responsible for developing spinal cord demyelinating diseases after SARS-CoV-2 infection may be either mediated by direct neurotropism or by unusual immune-mediated injury. Even though the pandemic is not there much, but the effect of this disease is still there. Thus, COVID-19 left a major impact on global demyelinating diseases therapeutics market.

Recent Developments

  • In March 2022, Teva Pharmaceutical Industries Ltd announced the launch of the first generic version of Revlimid, in dosage forms of 5mg, 10mg, 15mg and 25mg in the U.S. Teva’s Lenalidomide capsules are recommended for adults for the treatment of multiple myeloma along with the medicine dexamethasone.
  • In February 2022, Sanofi declared the completion of its acquisition of Amunix Pharmaceuticals, Inc. This will add a promising pipeline of T-cell engagers and cytokine therapies.
  • In September 2021, Novartis declared the acquisition of Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio.

Global Demyelinating Diseases Therapeutics Market Scope

The global demyelinating diseases therapeutics market is segmented on the basis of drug class, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Immunomodulators
  • Immunosuppressants
  • Interferons
  • Others

Route of Administration

  • Oral
  • Parenteral

End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Demyelinating Diseases Therapeutics Market Regional Analysis/Insights

The global demyelinating diseases therapeutics market is analysed and market size insights and trends are provided by drug class, route of administration, end-user, distribution channel as referenced above.

The major countries covered in the global demyelinating diseases therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is considered to have the highest lucrative growth in the forecast period due to the high-income of the countries, favourable reimbursement, high prevalence of demyelinating diseases and advanced healthcare facilities 

Asia-Pacific is dominating the market due to the rise in government initiatives and rapidly disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Demyelinating Diseases Therapeutics Market Share Analysis

The global demyelinating diseases therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global demyelinating diseases therapeutics market.

Key players operating in the global demyelinating diseases therapeutics market include:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Merck & Co., Inc. (U.S.)
  • Lilly (U.S.)
  • Amgen Inc. (U.S.)
  • Actelion Pharmaceuticals Ltd (Switzerland


SKU-

Why Choose Us


Frequently Asked Questions

The global demyelinating diseases therapeutics market was USD 0.71 billion in 2021.
The global demyelinating diseases therapeutics market is projected to grow at a CAGR of 10.50% during the forecast period of 2022-2029.
The major players in the market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Actelion Pharmaceuticals Ltd (Switzerland)
Asia-Pacific is dominating the market due to the rise in government initiatives and rapidly disposable income.